PT  - JOURNAL ARTICLE
AU  - Randol Kennedy
AU  - Hussein Awada
AU  - Naga Vura
AU  - Daniela Ciltea
AU  - Michael Morocco
TI  - Endocrinopathies from checkpoint inhibitors: Incidence, outcomes, and management
AID  - 10.3949/ccjm.90a.22032
DP  - 2023 May 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 307--317
VI  - 90
IP  - 5
4099  - http://www.ccjm.org/content/90/5/307.short
4100  - http://www.ccjm.org/content/90/5/307.full
SO  - Cleve Clin J Med2023 May 01; 90
AB  - Immune checkpoint inhibitors are used more and more to treat several types of cancer, significantly extending cancer-free survival. However, concerns are growing about their toxic effects, which are many and varied. Endocrinopathies are some of the most frequently reported adverse effects, and thyroid dysfunction is the most common of these. Here, we review the incidence and severity of each immune checkpoint inhibitor-related endocrinopathy, possible factors related to toxicity risk, and principles of management.